Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2

Attenuated poxvirus vectors MVA and NYVAC as promising vaccine cadidates against HIV/AIDS

(2014) Mariano Esteban   Human vaccines & immunotherapeutics

An Equine Herpesvirus Type 1 (EHV-1) Expressing VP2 and VP5 of Serotype 8 Bluetongue Virus (BTV-8) Induces Protection in a Murine Infection Model

(2012) Guanggang Ma et al.   PLoS One

Multiserotype Protection Elicited by a Combinatorial Prime-Boost Vaccination Strategy against Bluetongue Virus

(2012) Eva Calvo-Pinilla et al.   PLoS One

A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model

(2011) Javier Castillo-Olivares et al.   PLoS One

Complete Genome Characterisation of a Novel 26th Bluetongue Virus Serotype from Kuwait

(2011) Sushila Maan et al.   PLoS One

Detection of a Fourth Orbivirus Non-Structural Protein

(2011) Mourad Belhouchet et al.   PLoS One

Immunization of knock-out α/β interferon receptor mice against lethal bluetongue infection with a BoHV-4-based vector expressing BTV-8 VP2 antigen

(2011) Valentina Franceschi et al.   VACCINE

The Most Likely Time and Place of Introduction of BTV8 into Belgian Ruminants

(2010) Claude Saegerman et al.   PLoS One

Bluetongue in the United Kingdom and northern Europe in 2007 and key issues for 2008

(2010) J. Gloster et al.   VETERINARY RECORD

Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)

(2009) Rachael Chiam et al.   PLoS One

Establishment of a Bluetongue Virus Infection Model in Mice that Are Deficient in the Alpha/Beta Interferon Receptor

(2009) Eva Calvo-Pinilla et al.   PLoS One

Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(−/−) mice against lethal bluetongue infection

(2009) Eva Calvo-Pinilla et al.   VACCINE

Comparative safety study of three inactivated BTV-8 vaccines in sheep and cattle under field conditions

(2009) J. Gethmann et al.   VACCINE

Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines

(2009) Patricia L. Earl et al.   VACCINE

Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses

(2009) J.H.C.M. Kreijtz et al.   VACCINE

Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines

(2009) Zhongde Wang et al.   VACCINE

Viraemia and clinical disease in Dorset Poll sheep following vaccination with live attenuated bluetongue virus vaccines serotypes 16 and 4

(2009) Eva Veronesi et al.   VACCINE

IMVAMUNE®: modified vaccinia Ankara strain as an attenuated smallpox vaccine

(2008) Jeffrey S Kennedy et al.   Expert Review of Vaccines

Sequence analysis of bluetongue virus serotype 8 from the Netherlands 2006 and comparison to other European strains

(2008) Sushila Maan et al.   VIROLOGY

Vaccines against bluetongue in Europe

(2007) Giovanni Savini et al.   COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES

Use of real-time RT-PCR as a rapid molecular approach for differentiation of field and vaccine strains of bluetongue virus serotypes 2 and 9

(2007) Gabriella Elia et al.   MOLECULAR AND CELLULAR PROBES